- Researchers have found that the hormone FGF21 reversed obesity in mice by acting on a newly identified brain circuit in the hindbrain.
- Unlike GLP-1 drugs, which mainly reduce appetite, FGF21 appears to work by increasing energy burning.
- The findings are promising, but this is still mouse research and not proof that the same approach will work safely in people.
Scientists at the University of Oklahoma have identified how the hormone FGF21 reduces body weight in mice.
The key finding is that it works through the brain, not mainly through the liver as some might expect.
More specifically, it acts on a circuit in the hindbrain.
That was a surprise to the researchers, who had expected to find the main signal in the hypothalamus, a region more commonly linked to body weight control.
Instead, FGF21 was found to act through two hindbrain regions called the nucleus of the solitary tract and the area postrema.
These regions then signal onwards to the parabrachial nucleus.
According to the researchers, this circuit is essential for the hormone’s ability to reduce body weight.
What makes this especially interesting is that the hindbrain is also the general area where GLP-1 drugs are thought to act.
But the mechanism appears to be different.
GLP-1 drugs such as semaglutide mainly work by reducing appetite and food intake.
FGF21, by contrast, seems to work by raising metabolic activity and increasing the amount of energy the body burns.
That could matter because it points to a different route for weight loss treatment.
Instead of helping people eat less, it may help the body burn more.
The researchers say this could eventually help in the development of more targeted therapies for obesity and for MASH, the serious liver condition previously known as NASH.
- Hormone therapy plus tirzepatide linked to greater weight loss after menopause
- Next generation of obesity jab targets four hormones in quest for lasting weight loss
That said, there is no point pretending this is ready for clinical use.
This was a mouse study, not a human trial.
The researchers also note that FGF21-based drugs can come with side effects, including gastrointestinal problems and, in some cases, bone loss.
So while the biology is genuinely interesting, this is not the discovery of a natural cure for obesity.
It is a useful step in understanding how one hormone affects body weight, and it may help researchers design better treatments in future.
